Introducing Lecanemab, the Latest Alzheimer’s Disease Drug to Receive FDA Accelerated Approval

Dementia Matters

Content provided by Wisconsin Alzheimer‘s Disease Research Center. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Wisconsin Alzheimer‘s Disease Research Center or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

1+ y ago 20:48

MP3•Episode home

Host Nathaniel Chin, MD, gives an overview of the new Alzheimer’s treatment Leqembi (lecanemab), and highlights results from the second and third phases of its clinical trials. On January 6, 2023, the U.S. Food and Drug Administration (FDA) approved Leqembi (lecanemab-irmb) via the Accelerated Approval pathway for the treatment of Alzheimer’s disease.

Show Notes

In the coming weeks, host Nathaniel Chin will be joined by Cynthia Carlsson, MD, MS, and Sterling Johnson, PhD, to further discuss lecanemab and the clinical trials’ results. A link to that episode will be added here following its release.

Read the FDA’s news release regarding lecanemab’s accelerated approval on their website.

Connect with us

Find transcripts and more at our website.

Email Dementia Matters: dementiamatters@medicine.wisc.edu

Subscribe to the Wisconsin Alzheimer’s Disease Research Center’s e-newsletter.

100 episodes

#Science #Fitness #Medicine #Wisconsin Alzheimer's Disease Research Center